Axsome Therapeutics price target raised to $200 from $190 at Truist

Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 results saw “no surprises” to its pre-announcement, and more importantly, its Phase 3 study of solriamfetol in ADHD remain on track for Q1, the analyst tells investors in a research note. . As a DEA Schedule IV drug, if approved for ADHD, solriamfetol may be favored over other ADHD drugs such as Ritalin, Adderall, Vyvanse, etc, the firm adds.